Bristol-Myers Squibb (BMY) DIvidends Date & History

Key Takeaways

• Bristol-Myers Squibb offers a current dividend yield of approximately 4.36%, attractive for income-focused investors in the pharmaceutical sector.
• The company pays a quarterly dividend of $0.63 per share, equating to an annual payout of $2.52.
• BMY has increased its dividend for 17 consecutive years and paid dividends for 94 consecutive years.
• Payout ratio stands at around 72%, indicating solid earnings coverage, with free cash flow providing even stronger support.
• Dividend appears sustainable despite patent challenges, backed by robust free cash flow of $13.9 billion in 2024.
• Yield is competitive, higher than peers like JNJ (~3%) and MRK (~2.5%), but below PFE (~7%).

Dividend Overview

Bristol-Myers Squibb maintains a consistent quarterly dividend policy, distributing $0.63 per share, for an annual total of $2.52. This yields approximately 4.36% based on recent stock prices. The most recent ex-dividend date was April 2, 2026, with payment on May 1, 2026. As a large-cap pharmaceutical company, BMY positions itself as a high-yield dividend stock rather than a rapid growth payer, appealing to investors seeking reliable income amid sector volatility. Its long history of payments underscores a commitment to shareholder returns, though growth has been modest recently at 1.6% year-over-year.

Dividend History and Growth

Bristol-Myers Squibb has a storied dividend history, marking 94 consecutive years of payments and 17 straight years of increases as of the latest declaration in December 2025, when the quarterly payout rose from $0.62 to $0.63. Over the past five years, the dividend yield has averaged 3.92%, reflecting steady progression despite acquisitions and pipeline investments. The company has avoided cuts in recent decades, prioritizing consistent returns. This track record positions BMY as a near-Dividend Aristocrat contender, though it falls short of the 25-year increase threshold. Management views the dividend as a core element of its capital allocation strategy, balancing R&D, debt reduction, and buybacks.

Dividend Sustainability and Payout Ratio

The dividend's sustainability is supported by a payout ratio of approximately 72%, leaving room for reinvestment while covering obligations from earnings per share (EPS) of $3.46 trailing twelve months (TTM). Free cash flow (FCF) coverage is even more robust at around 40% payout relative to cash generation, with 2024 FCF reaching $13.9 billion, up 10% year-over-year. Debt levels are manageable and declining, with a debt-to-FCF ratio of 3.51, signaling ability to handle maturities without strain. Despite patent expirations, a strong oncology and immunology pipeline bolsters long-term confidence in coverage.

Dividend Compared to Industry Peers

Bristol-Myers Squibb's 4.36% yield outpaces many large pharma peers, such as JNJ at around 3% and MRK near 2.5-3%, making it more appealing for yield hunters. It aligns closely with ABBV's profile but trails PFE's higher 6-7% payout, which carries greater risk from its own challenges. BMY's combination of yield, growth streak, and FCF strength gives it a competitive edge in the sector for balanced income exposure.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to streamline your research and uncover hidden gems in sectors like pharmaceuticals.

Is This Stock Attractive for Dividend Investors?

Bristol-Myers Squibb appeals to income investors prioritizing high yields in a defensive sector, offering 4.36% with quarterly payouts and a 17-year growth streak. Conservative investors may value its 94-year payment history and FCF-backed sustainability amid healthcare demand. Dividend growth enthusiasts could appreciate modest annual hikes, though not at aristocrat levels. However, patent cliffs and R&D costs introduce volatility, suiting those comfortable with pharma risks over pure stability seekers favoring lower-yield stalwarts like JNJ. Long-term holders might weigh pipeline potential against peers. Overall, BMY fits portfolios blending yield and moderate growth without excessive speculation.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations